A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)

被引：0
|
作者：
Beaufils, M. [1 ]
Mailliez, A. [2 ]
Sfumato, P. [3 ]
Vicier, C. [1 ]
Gross, M. Provansal [1 ]
Guerin, M. [1 ]
Chanez, B. [1 ]
Kotecki, N. [4 ]
Widemann, A. [5 ]
Panzolato, S. [6 ]
Chammard, A. Boyer [7 ]
Andre, P. [8 ]
Paturel, C. L.
Gouarne, C.
Awada, A. H.
Boher, J. M. [3 ]
Goncalves, A. [1 ]
机构：
[1] IPC Inst Paoli Calmettes, Med Oncol Dept, Marseille, France
[2] Ctr Oscar Lambret, Med Oncol Dept, Marseille, France
[3] IPC Inst Jules Bordet, Dept Clin Res, Brussels, Belgium
[4] Inst Jules Bordet, Oncol Med Dept, Brussels, Belgium
[5] Innate Pharma, Clin Pharmacol, Marseille, France
[6] Innate Pharma, Clin Operat, Marseille, France
[7] Innate Pharma, Marseille, France
[8] Innate Pharma, Res & Drug Dev, Marseille, France
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003P
引用
收藏
页码：S682 / S683
页数：2
相关论文
共 50 条
  • [21] First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
    Elez, Elena
    Gomez-Roca, Carlos
    Soto Matos-Pita, Arturo
    Argiles, Guillem
    Valentin, Thibaud
    Coronado, Cinthya
    Iglesias, Jorge
    Macarulla, Teresa
    Betrian, Sarah
    Fudio, Salvador
    Zaragoza, Katrin
    Tabernero, Josep
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 674 - 683
  • [22] First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
    Shitara, Kohei
    Uehai, Satoshi
    Shichino, Shigeyuki
    Aoki, Hiroyasu
    Ogiwara, Haru
    Nakatsura, Tetsuya
    Suzuki, Toshihiro
    Shimomura, Manami
    Yoshikawa, Toshiaki
    Shoda, Kayoko
    Kitano, Shigehisa
    Yamashita, Makiko
    Nakayama, Takayuki
    Sato, Akihiro
    Kuroda, Sakiko
    Wakabayashi, Masashi
    Nomura, Shogo
    Yokochi, Shoji
    Ito, Satoru
    Matsushima, Kouji
    Doi, Toshihiko
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 : 195
  • [23] First-in-human (FIH) phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib with milled formulation in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Chen, Yu-ling
    Jia, Ru
    Shen, Lin
    Wang, Jian
    Sai, Yang
    Qi, Chuan
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] A phase Ia first-in-human study of JS']JS007, a novel anti-CTLA-4 monoclonal antibody, in patients with advanced solid tumors
    Zhang, J.
    Zhou, C.
    Jiang, J.
    Liu, H.
    Xiang, X.
    Wu, G.
    Zeng, R.
    Kuang, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S633 - S633
  • [25] A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Kelley, Robin Kate
    Tolcher, Anthony W.
    Razak, Albiruni R. Abdul
    Van Loon, Katherine
    Patnaik, Amita
    Bedard, Philippe L.
    Alfaro, Ariceli A.
    Beeram, Muralidhar
    Adriaens, Lieve
    Brownstein, Carrie M.
    Lowy, Israel
    Kostic, Ana
    Trail, Pamela A.
    Gao, Bo
    DiCioccio, A. Thomas
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1348 - 1355
  • [26] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
    Meulendijks, Didier
    Jacob, Wolfgang
    Martinez-Garcia, Maria
    Taus, Alvaro
    Lolkema, Martijn P.
    Voest, Emile E.
    Langenberg, Marlies H. G.
    Fleitas Kanonnikoff, Tania
    Cervantes, Andres
    De Jonge, Maja J.
    Sleijfer, Stefan
    Soerensen, Morten Mau
    Thomas, Marlene
    Ceppi, Maurizio
    Meneses-Lorente, Georgina
    James, Ian
    Adessi, Celine
    Michielin, Francesca
    Abiraj, Keelara
    Bossenmaier, Birgit
    Schellens, Jan H. M.
    Weisser, Martin
    Lassen, Ulrik N.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 877 - 885
  • [27] A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors
    Lassen, U.
    Schellens, J. H. M.
    Siu, L. L.
    Jonker, D. J.
    Sorensen, M.
    Jarutat, T.
    Wang, K.
    Gehoe, D.
    DeMario, M.
    Goss, G.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 12 - 12
  • [28] First-in-human phase I trial of the anti-CEACAM5 antibody-drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)
    Gazzah, A.
    Stjepanovic, N.
    Ryu, M. H.
    Tabernero, J.
    Soria, J. C.
    Bedard, P.
    Kang, Y. K.
    Bahleda, R.
    Guillemin-Paveau, H.
    Henry, C.
    Hatteville, L.
    Zilocchi, C.
    Demers, B.
    Hierro, C.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S14 - S15
  • [29] Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
    Jayson, Gordon C.
    Mullamitha, S.
    Ton, C.
    Valle, J.
    Saunders, M.
    Munteanu, M. C.
    Jiao, Q.
    Davis, H. M.
    Lang, Z.
    Beckman, R. A.
    ANNALS OF ONCOLOGY, 2004, 15 : 102 - 102
  • [30] Phase I study of CNTO 95, a fully human monoclonal antibody (mAb) to αv integrins, in patients with solid tumors
    Jayson, GC
    Mullamitha, S
    Ton, C
    Valle, J
    Saunders, M
    Munteanu, MC
    Jang, H
    Trikha, M
    Davis, HM
    Beckman, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 224S - 224S
12345